succinobucol
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 2003 (NCT00066898)
Timeline
Indications
Mechanism of action
- Unspecified targetOTHER
Antioxidant, anti-inflammatory, antiplatelet
- Unspecified targetAntioxidant
Antioxidant
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(OC(=O)CCC(=O)O)c(C(C)(C)C)c1- Mol. weight
- 616.93 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL83626 ↗
Also known as
- agi1067
- agi 1067
- agi-1067
- agi-1067
- agi-1067
- succinobucol
- succinobucol
- succinobucol
- succinobucol
- succinobucol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00525577 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2007 | AtheroGenics |
| NCT00066898 | Phase 3 | Jun 1, 2003 | AtheroGenics, Harvard University, University of Montreal, Western Infirmary |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AtheroGenics | For profit | 2 | 2 | 1 | 2003 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Montreal | Academic/Hospital | 1 | 0 | 1 | 2003 |
| Western Infirmary | Academic/Hospital | 1 | 0 | 1 | 2003 |
4 organizations
Page 1 / 1